Clinical Trials Logo

Gastritis clinical trials

View clinical trials related to Gastritis.

Filter by:

NCT ID: NCT03003234 Completed - Clinical trials for Functional Dyspepsia

Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia

Start date: March 2015
Phase: N/A
Study type: Interventional

Functional dyspepsia (FD) is an extremely common disorder of gastrointestinal function. Recently, impaired duodenal mucosal integrity was reported as a potential pathophysiological mechanism in FD. However, the factors controlling duodenal mucosal integrity remain unknown. In this study, we evaluated whether the luminal bile salt content could play a role in impaired duodenal permeability in FD. Duodenal biopsies were obtained from 25 healthy volunteers (HV) and 25 FD patients. Biopsies were mounted in Ussing chambers to measure transepithelial resistance (TEER) and paracellular permeability using fluorescein isothiocyanate dextran (FITC-dx4, MW 4kDa). Expression of bile acid-sensing receptors (TGR5, VDR, PXR, FXR and CAR) in duodenal biopsies was measured by western blot and real time RT-PCR. Immunohistochemistry was used to evaluate eosinophil and mastcell infiltration in duodenal biopsies of FD patients and HV. Duodenal fluid aspirates were collected at fixed time points during 1 hour in fasted state and 1.5 hours after a liquid meal (Nutridrink, 200ml). Concentration and composition of the bile salt pool (including glycocholic acid (GC), taurocholic acid (TC), glycochenodeoxycholic acid (GCDC), taurochenodeoxycholic acid (TCDC), glycodeoxycholic acid (GDC), taurodeoxycholic acid (TDC), glycoursodeoxycholic acid (GUDC) and tauroursodeoxycholic acid (TUDC)) in these aspirates was evaluated by liquid chromatography-mass spectrometry-selected ion monitoring analysis (LC-MS/MS).

NCT ID: NCT02996604 Completed - Clinical trials for Functional Dyspepsia

Acupuncture for Functional Dyspepsia: a Functional Magnetic Resonance Imaging (fMRI) Study

Start date: January 2017
Phase: N/A
Study type: Interventional

He-Mu-point combination(ST36 and CV12) is one of the most commonly used acupoints combination with synergistic effect for functional dyspepsia(FD). The investigators design the trial to identify the efficacy and explore the central integrated mechanism of puncturing at He-Mu-point combination on FD with functional magnetic resonance imaging (fMRI).

NCT ID: NCT02961296 Not yet recruiting - Lymphoma Clinical Trials

Helicobacter Pylori Antibiotic Susceptibility Testing of Korea

Start date: October 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to make nationwide registry for antimicrobial resistance of Helicobacter pylori using single method with agar dilution in Korea.

NCT ID: NCT02955134 Completed - Clinical trials for Chronic Atrophic Gastritis

The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis

Start date: March 12, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.

NCT ID: NCT02923856 Recruiting - Gastritis Clinical Trials

A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin

Start date: January 2017
Phase: N/A
Study type: Interventional

As the resistant rate of the Helicobacter pylori to some common antibiotics was rising,the eradication rate of the Helicobacter pylori with the standard triple therapy failed to exceed 70% in China,and had to drop out of the first-line treatment recommendations. However, with the increase of treatment time, patients burden, adverse reactions of antibiotics or proton pump inhibitor (PPI) will also increase. Resistance to clarithromycin is the major cause of the failure to eradicate Helicobacter pylori. But, in terms of population, there are still more than 70% of the patients with clarithromycin sensitive. Under the guidance with susceptibility test,7-day standard triple therapy could be used. In this study, investigators will select the patients with infection of H. pylori and with clarithromycin sensitive. Eradication of Helicobacter pylori with triple therapy based on accurate susceptibility testing of clarithromycin will be studied. The treatment time will be assigned into 7 days,10 days and 14 days groups. Then, investigators will perform a sequencing for failed treatment patients in groups, such as drug resistance gene mutation, phenotype and genotype. Finally, investigators will compare the differences between the patients with triple therapy and traditional quadruple therapy.The incidence of adverse effects in the eradicate treatment will reduce at least 10% and avoid patients' unnecessary economic losses at least 400RMB per person.

NCT ID: NCT02915393 Not yet recruiting - Gastric Cancer Clinical Trials

System Biology of Spleen Deficiency Syndrome

SBSDS
Start date: September 2016
Phase: N/A
Study type: Observational

Spleen Deficiency Syndrome(SDS)is a widely researched issue, but due to the limitations of the research methods, the scientific mechanism of SDS is biased and not comprehensive. SDS would be researched in this project deeply and systematically with modern life-scientific methods. Based on the previous work, the participants, with SDS, suffering from Qi deficiency syndrome--chronic superficial gastritis--chronic atrophic gastritis--gastric cancer would be included, and the corresponding research would be conducted at the molecular-cell-gastric tissue level, and at the same time, systematical biological database of SDS would be built by systematical biological methods, such as pioneered SPARS sequencing technology created in our research group, proteomics and metabonomics. Under the above work, the investigators would conduct data mining and molecular network analysis, and then verify the key functions. By analyzing the systematical biological features of syndrome and its relationships with constitution and disease, this study would provide a new basis for objective reality of syndrome, and also offer a crucial premise of revealing biological basis for syndrome correctly, which is of important theoretical and practical significance.

NCT ID: NCT02897271 Completed - Clinical trials for Eosinophilic Esophagitis

Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort

Start date: August 2016
Phase:
Study type: Observational

The purpose of this study is to investigate features of patients with Eosinophilic Gastrointestinal Disorders (EGIDs) other than Eosinophilic Esophagitis (EoE) alone, including Eosinophilic Gastritis (EG), Eosinophilic Gastroenteritis (EGE), and Eosinophilic Colitis (EC).

NCT ID: NCT02884713 Completed - GASTRITIS Clinical Trials

Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia

Start date: June 2013
Phase: N/A
Study type: Interventional

Helicobacter pylori (H. pylori) eradication is achieved in 60-80% with first-line therapy. Different second-line therapeutic options are available. However, the success of second-line therapy has not been addressed or reported from Saudi Arabia. Objectives The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment.

NCT ID: NCT02833363 Recruiting - Gastric Cancer Clinical Trials

Difference of Gastric Microbiota in the Process of Correa's Model.

Start date: July 2016
Phase: Phase 4
Study type: Observational

Helicobater pylori plays an important role in the development of gastric cancer. Eradication therapy can reducing the morbidity of gastric cancer, but can't totally prevent it especially when atrophy and more serious precancerous lesions already happened. Prior studies found the gastric bacterial difference among gastritis, intestinal metaplasia and gastric cancer. However, they didn't reach an agreement. Correa's model is widely accepted in the development of gastric cancer. The pathological change makes a more suitable environment for bacteria to overgrowth. This study are designed to analyze the gastric microbial difference of non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.

NCT ID: NCT02827942 Completed - Clinical trials for Gastritis Associated With Helicobacter Pylori

Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

Start date: July 1, 2016
Phase: Phase 3
Study type: Interventional

Patients infected with H. pylori were randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg or metronidazole 250 mg bid bid for 1 week. Success or failure of eradication was determined by the 13C-urea breath test performed at 1 month after the therapy.